	US 12,274,784 B2
	Methods for reducing side effects of immunotherapy
Esther H. Chang, Potomac, MD (US); Joe B. Harford, Potomac, MD (US); and Sang Soo Kim, Rockville, MD (US)
Assigned to SYNERGENE THERAPEUTICS, INC., Potomac, MD (US); and GEORGETOWN UNIVERSITY, Washington, DC (US)
Filed by SYNERGENE THERAPEUTICS, INC., Potomac, MD (US); and GEORGETOWN UNIVERSITY, Washington, DC (US)
Filed on Oct. 10, 2019, as Appl. No. 16/597,861.
Claims priority of provisional application 62/745,217, filed on Oct. 12, 2018.
Prior Publication US 2020/0113829 A1, Apr. 16, 2020
Int. Cl. A61K 9/127 (2006.01); A61K 31/282 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07K 16/28 (2006.01)

CPC A61K 9/127 (2013.01) [A61K 31/282 (2013.01); A61K 38/1709 (2013.01); A61K 38/1758 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2881 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01)]

10 Claims

1. A method of treating a cancer in a patient, consisting of:

a. providing a transferrin-receptor-targeted cationic liposomal complex, comprising:

i. a cationic liposome;

ii. an anti-transferrin receptor single chain Fv (TfRscFv) complexed with the cationic liposome, but not chemically conjugated to the cationic liposome, and wherein the TfRscFv does not comprise a lipid tag; and

iii. a nucleic acid encoding p53;

b. administering intravenously only the transferrin-receptor-targeted cationic liposomal complex in combination with an immune checkpoint modulator to the patient; and

c. delivering the nucleic acid encoding p53 via the transferrin-receptor targeted cationic liposomal complex to immune cells in the patient and the immune checkpoint modulator to immune cells in the patient;

d. enhancing an innate anti-tumor immune response triggered by the immune cells of the patient; and

e. enhancing an adaptive immunity response triggered by the immune cells of the patient.